K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$1,221.10
Prev. Close
$1,215.87
Prev. Day's Range
$1,204.16 - $1,241.89
52W Range
$619.40 - $1,249.45
Trading Volume
2.082M
MC
$1101.8B
P/E Ratio
42.5x
EPS
$29.04
Company Overview
NYSE
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
HeadquartersLILLY CORPORATE CENTER, INDIANAPOLIS, IN, UNITED STATES, 46285
Settled in USDT, supports up to 20x leverage, allows for two-way trading (long/short), no need to hold underlying assets, suitable for short-term trend trading and hedging.
Eli Lilly and Company (LLY) is a global pharmaceutical firm that specializes in the development, manufacturing, and marketing of medicines. Its core business focuses on treating conditions like diabetes, oncology, immunology, and neuroscience. The company aims to improve patient health through innovative drug therapies.
LLY operates in the healthcare sector, specifically within the pharmaceutical industry. The company is involved in research and development, manufacturing, and commercialization of medicines across various therapeutic areas.
Eli Lilly’s revenue primarily comes from its innovative drugs targeting diabetes, cancer, autoimmune diseases, and neurological disorders. Key products include Trulicity for diabetes and Verzenio for breast cancer. The company also benefits from patent-protected medications and the expansion of global distribution channels.
Yes, Eli Lilly pays dividends to its shareholders. Historically, the company has maintained a regular dividend payout, reflecting its commitment to returning value to investors. Please refer to the latest investor relations materials for updated dividend yield and payment schedules.
LLY’s opportunities include expanding its portfolio of innovative drugs, leveraging new technologies in drug discovery, and addressing unmet medical needs in areas like oncology and autoimmune diseases. The company’s investment in R&D positions it to capture growth in emerging global markets.
Investors should be aware of risks like regulatory challenges, drug patent expirations, and competition from generic and biosimilar drugs. Additionally, the pharmaceutical industry is subject to pricing pressures and potential litigation risks, which could impact profitability.
LLY competes with other major pharmaceutical companies such as Pfizer and Merck. Its focus on innovative therapies and strong R&D pipeline differentiates it. However, competition in specific drug categories and pricing pressures remain ongoing challenges.
Eli Lilly’s long-term growth relies heavily on its commitment to research and development (R&D). Through significant investment in R&D, the company aims to create breakthrough drugs, maintain a robust pipeline, and sustain competitiveness in a rapidly evolving pharmaceutical landscape.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
